Alternatives to SonoThera

Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).

Biopharmaceutical company developing novel small-molecule therapeutics for rare kidney diseases, particularly Autosomal Dominant Polycystic Kidney Disease (ADPKD).

A biotechnology company developing gene therapy treatments for rare, debilitating genetic diseases.

A biotechnology company developing genetic therapies for rare disorders.

Developing gene editing therapies to lower cholesterol.

Clinical-stage biopharmaceutical company developing next-generation therapies for obesity and cardiometabolic diseases.

Pioneering vision restoration therapies for severe retinal degenerations.

Developing novel male contraceptives.

Develops and distributes bioreactor technology for stem cell cultivation.

Developing a new histotripsy therapeutic platform for cancer treatment.

Elevating uterine health through innovative biomaterial therapies.

Develops multimodal hemoadsorption therapeutic devices for sepsis and septic shock.

A clinical-stage dermatology company developing novel therapies for inflammatory skin diseases.

Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.

Clinical-stage biotechnology company developing multi-mechanistic oncolytic immunotherapy programs for cancer treatment.

Clinical-stage biotechnology company advancing molecular glue degrader (MGD) medicines.

Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.

A clinical-stage biotechnology company developing inobrodib as a first-in-class, oral p300/CBP inhibitor for the treatment of multiple myeloma.

Developing human-derived antibodies for inflammatory diseases and cancer using AI and proprietary platforms.

Clinical-stage biopharmaceutical company leveraging a proprietary platform to discover and develop novel precision medicines from fungi.

Developing first-and best-in-class antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

Personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy.

A global leader in clinical pharmacology and bioanalytical sciences.

Freenome is a biotechnology company developing a multi-cancer early detection blood test using machine learning and biology.

Developing novel immunotherapies and diagnostics for cancer.

A clinical-stage biopharmaceutical company developing novel immunotherapies.

A clinical-stage biopharmaceutical company developing novel therapies for neurological disorders.

Clinical-stage biopharmaceutical company developing novel treatments for exocrine pancreatic insufficiency.

Biotechnology company developing next-generation gene therapies using a proprietary protein splicing platform.

A biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension.

Engineering scalable gene therapies for broader patient populations.

The first Integrated Development and Manufacturing Organization (IDMO) for cell therapies.

Developing oral small molecule medicines for immunological and chronic diseases.

Advancing deupirfenidone as a potential new standard of care for Idiopathic Pulmonary Fibrosis (IPF).

An end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials, focusing on lung and heart disease.

A clinical-stage biopharmaceutical company developing novel cell therapies for AL Amyloidosis and other serious diseases.

A full-stack spatial biology company.

Developing a new class of anti-IgE therapy for multiple atopic conditions.

Advancing clinical stage pipeline targeting new and major neurology and neuropsychiatric disorders.

A biopharmaceutical company focused on developing and commercializing therapies for rare diseases.

Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies.

A biotechnology company focused on developing novel enzyme-based therapies for reflux disease.

Provides regulated, secure, and high-yield digital asset solutions for institutional and corporate treasuries.

Immunotherapy company targeting oncology and autoimmune diseases.

Developing magnetic cell delivery platform for advanced therapies.

Developing first-in-class oral therapy for BK polyomavirus infections.

Developing epigenetic reprogramming drugs for age restoration.

A biopharmaceutical company developing RNA interference (RNAi)-based medicines.

Advancing scalable microbiome-based therapeutics for severe and chronic diseases.

Clinical-stage biopharmaceutical company developing transformative, best-in-class neuropsychiatric therapies.

Developing microbiome-based therapeutics to address underlying disease biology, particularly in gastrointestinal health.

Scalable, one-time curative in-vivo gene editing therapies.

Clinical-stage immunotherapy company developing novel treatments for cancer.

Platform designed to cut cell and gene therapy production costs.

A biopharmaceutical company focused on drug discovery and development.

Advancing targeted alpha therapies.

AI-enabled technology for cell biology research and biopharma development.

Biopharmaceutical company developing innovative therapies for sepsis and intensive care.

A commercial-stage immunotherapy company developing novel treatments for cancer and infectious diseases.

Clinical-stage biopharmaceutical company developing treatments for brain and peripheral disorders involving the CB1 receptor.